medigraphic.com
Academia Mexicana de Neurología, A.C.

2014, Number 1

<< Back Next >>

Rev Mex Neuroci 2014; 15 (1)

Adherence and perception of antiparkinsonic therapy in Mexican patients with Parkinson’s disease

Cervantes-Arriaga A, Rodríguez-Violante M, Bazán-Rodríguez L, de la Cruz-Landero A, Camacho-Ordóñez A, González-Latapi P, Velázquez-Osuna S

Language: Spanish
References: 28
Page: 11-17
PDF size: 162.75 Kb.


ABSTRACT

Introduction: Non-adherence to drug therapy is one of the main problems in providing medical management for patients with Parkinson’s disease. The factors involved are many and include clinical and socio-demographic aspects. These factors have not been described in Mexican patients.
Objetive: To determine the level of adherence and perceptions about treatment of Mexican patients with Parkinson’s disease.
Material and Methods: A cross-sectional study was conducted in patients with Parkinson’s disease. Clinical and demographic data including antiparkinsonic treatment were recorded. The following clinical instruments were applied: Movement Disorders Society Unified Parkinson’s Disease Rating Scale, Morisky-Green Questionnaire, Brief Medication Questionnaire and the Beliefs about Medicines Questionnaire.
Results: A total of 64 patients (33 men) were included, the mean age was 59.2 ± 14.5 years. Low adherence was found in 32.8 % of the patients; intermediate adherence on 31.3 %and high adherence on 35.9 %. The 18.8% of the patients reported suspending their antiparkinsonic drugsby choice in the last six months; 56.2 % say they worry about side effects, although 90.7% recognized the benefit of treatment. A younger age (p = 0.005), early age of onset (p = 0.001) and having employment (p = 0.043) were the factors associated with a high adherence.
Conclusions: Adherence in the studied sample is less than that reported in other countries. Age and employment have a very important role in treatment adherence.


REFERENCES

  1. Jankovic J. Parkinson’s disease and movement disorders: moving forward. Lancet Neurol 2008; 7: 9-11.

  2. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamics properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261-309.

  3. Agúndez JA, García-Martín E, Alonso-Navarro H, Jiménez-Jiménez FJ. Anti-parkinson’s disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol 2013; 9: 859-74.

  4. Fabbrini G, Abbruzzese G, Barone P, Antonini A, Tinazzi M, Castegnaro G, et al. Adherence to anti-Parkinson drug therapy in the “REASON” sample of Italian patients with Parkinson’s disease: the linguistic validation of the Italian version of the “Morisky Medical Adherence scale-8 items”. Neurol Sci 2013; 34: 2015-22.

  5. Bainbridge JL, Ruscin JM. Challenges of treatment adherence in older patients with Parkinson’s disease. Drugs Aging 2009; 26: 145-55.

  6. Santos-García D, Prieto-Formoso M, de la Fuente-Fernández R. Levodopa dosage determines adherence to long-acting dopamine agonists in Parkinsons disease. J Neurol Sci 2012;‘318: 90-3.

  7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.

  8. Martínez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s disease rating scale (MDS-UPDRS). J Neurol 2013; 260: 228-36.

  9. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.

  10. Starsvad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 1999; 37: 113-24.

  11. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychology Health 1999; 14: 1-24.

  12. Daley DJ, Myint PK, Gray RJ, Deane KH. Systematic review on factors associated with medication non-adherence in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: 1053-61.

  13. Grosset D, European PD Therapy Compliance Study Group. J Neurol Sci 2010; 289: 115-18.

  14. Delea TE, Thomas SK, Hagiwara M. The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson’s disease: a retrospective claims-based analysis. CNS Drugs 2011; 25: 53-66.

  15. Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims data. Mov Disord 2010; 25: 474-80.

  16. Marchi KC, Chagas MH, Tumas V, Miasso AI, Crippa JA, Tirapeli CR. Adherence to medication among patients with Parkinson’s disease treated at a specialized outpatiente unit. Cien Saude Colet 2013; 18: 855-62.

  17. Valldeoriola F, Coronell C, Pont C, Buongiorno MT, Cámara A, Gaig C, ADHESON Study Group, et al. Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson’s disease: the ADHESION study. Eur J Neurol 2011; 18: 980-7.

  18. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, et al. Adherence to antiparkinson medications in a multicenter European study. Mov Disord 2009; 24: 826-32.

  19. Wei YJ, Palumbo FB, Simoni-Wastila L, Shulman LM, Stuart B, Beardsley R, et al. Antiparkinson drug use and adherence in medicare part d beneficiaries with Parkinson’s disease. CLin Ther 2013; 35: 1513-25.

  20. Murphy R, Tubridy N, Kevelighan H, O’Riordan S. Parkinson’s disease: how is employment affected? Ir J Med Sci 2013; 182: 415-9.

  21. Tarrants ML, Denarié MF, Castelli-Haly J, Millard J, Zhand D. Drug therapies for Parkinson’s disease: a database analysis of patient compliance and persistance. Am J Geriatr Pharmacother 2010; 8: 374-83.

  22. Buetow S, Henshaw J, Bryant L, O’Sullivan D. Medication timing errors for Parkinson’s disease: perspectives held by caregivers and people with Parkinson’s study in New Zeleand. Parkinsons Dis 2010; 432983. Doi: 10.4061/2010/432983.

  23. Giladi N. Medical treatment of freezing of gait. Mov Disord 2008; 23: 482-8. Cervantes-Arriaga Amin, et al. Adherencia en enfermedad de Parkinson Rev Mex Neuroci Enero-Febrero, 2014; 15(1): 11-17 17

  24. Pickering RM, Fitton C, Ballinger C, Fazakarley L, Ashburn A. Self reported adherence to a home-based exercise programme among people with Parkinson’s disease. Parkinsonism Relat Disord 2013; 19: 66-71.

  25. Sturkenboom IH, Graff MJ, Borm GF, Veenhuizen Y, Bloem BR, Munneke M, et al. The impact of occupational therapy in Parkinson’s disease: a randomized controlled feasibility study. Clin Rehabil 2013; 27: 99-112.

  26. Wright J, Walker J. Medication adherence in Parkinson’s. Br J Nurs 2013: 22: 686-9.

  27. Drey N, McKeown E, Kelly D, Gould D. Adherence to antiparkinsonian medication: an in-depth qualitative study. Int J Nurs Stud 2012; 49: 863-71.

  28. Daley DJ, Deane KH, Gray RJ, Worth PF, Clark AB, Sabanathan K, et al. The use of carer assisted adherence therapy for people with Parkinson’s disease and their carers (CAAT-PARK): study protocol for a randomized controlled trial. Trials 2011; 12: 251.doi: 10.1186/ 1745-6215-12-251.




2020     |     www.medigraphic.com